Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 9;12:5343. doi: 10.1038/s41467-021-25697-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — MPSIVA rats were treated intravascularly with 6.67 × 10¹³ vg/kg AAV9-Galns vectors at 4 weeks of age. a LIMP2 immunohistochemical analysis of humeral articular cartilage sections from 2-months-old WT, untreated and AAV9-Galns-treated MPSIVA rats. Articular chondrocytes from MPSIVA rats presented severe lysosomal distension that was markedly reduced after AAV9-Galns treatment. Scale bars: 50 µm. AC articular cartilage, SC synovial cavity. b Quantification of LIMP2 mean fluorescence in articular cartilage of 2-months-old WT (n = 4), untreated (n = 7) and AAV9-Galns-treated (n = 6) MPSIVA rats. c KS content in the distal femoral epiphysis of 6-months-old WT, untreated and AAV9-Galns-treated MPSIVA rats (n = 3 animals/group). d Safranin O staining of histological sections of humerus articular cartilage of 6-months-old WT, untreated and AAV9-Galns-treated MPSIVA rats (n = 3 animals/group). Scale bars, 50 µm; insets, 20 µm. SB subchondral bone, SL superficial layer. e Ultrastructural analysis of SL from tibial articular cartilage of 6-months-old WT, untreated and AAV9-Galns-treated MPSIVA rats. Large electrolucent vacuoles (arrows) were detected in chondrocytes of untreated MPSIVA rats, that were absent after AAV9-Galns treatment. n = 2 animals/group. Scale bars, 5 µm. f Grip strength analysis of 2- and 6-months-old WT (n = 9, 6, respectively), untreated (n = 11, 6, respectively) and AAV9-Galns-treated (n = 10, 7, respectively) MPSIVA rats. All results are shown as mean ± SEM and P-values of one-way Anova test are indicated (95% confidence interval). *P < 0.05, **P < 0.01, and ***P < 0.001 vs. untreated MPSIVA rats. Source data are provided as a Source Data file.